{"nctId":"NCT01959347","briefTitle":"Combined Treatment for Mixed Incontinence","startDateStruct":{"date":"2013-10-28"},"conditions":["Urinary Incontinence, Stress","Urinary Incontinence, Urge"],"count":480,"armGroups":[{"label":"Miduretheral Sling (Control)","type":"SHAM_COMPARATOR","interventionNames":["Procedure: Miduretheral Sling"]},{"label":"MUS+BPTx","type":"EXPERIMENTAL","interventionNames":["Other: Miduretheral Sling with behavioral/pelvic floor therapy"]}],"interventions":[{"name":"Miduretheral Sling","otherNames":["MUS"]},{"name":"Miduretheral Sling with behavioral/pelvic floor therapy","otherNames":["MUS + BPTx"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Presence of both SUI and UUI on bladder diary; and \\> 2 IEs/3 days\n\n   1. \\> 1 Stress IE/3 day diary\n   2. \\> 1 Urge IE/3 day diary\n2. Reporting at least \"moderate bother\" from UUI item on the UDI \"Do you usually experience urine leakage associated with a feeling of urgency, that is a strong sensation of needing to go to the bathroom?\"\n3. Reporting at least \"moderate bother\" from SUI item on UDI \"Do you usually experience urine leakage related to coughing, sneezing, or laughing\"\n4. Diagnosis of SUI defined by a positive cough stress test (CST) or urodynamic evaluation within the past 18 months\n5. Desires surgical treatment for SUI symptoms\n6. Urinary symptoms \\>3 months\n7. Subjects understand that BPTx is a treatment option for MUI outside of ESTEEM study protocol\n8. Urodynamics within past 18 months\n\nExclusion Criteria:\n\n1. Anterior or apical compartment prolapse at or beyond the hymen (\\>0 on POPQ), regardless if patient is symptomatic\n\n   a)Women with anterior or apical prolapse above the hymen (\\<0) who do not report vaginal bulge symptoms will be eligible\n2. Planned concomitant surgery for anterior vaginal wall or apical prolapse \\> 0\n\n   a)Women undergoing only rectocele repair are eligible\n3. Women undergoing hysterectomy for any indication will be excluded\n4. Active pelvic organ malignancy\n5. Age \\<21 years\n6. Pregnant or plans for future pregnancy in next 12 months, or within 12 months post-partum\n7. Post-void residual \\>150 cc on 2 occasions, or current catheter use\n8. Participation in other trial that may influence results of this study\n9. Unevaluated hematuria\n10. Prior sling, synthetic mesh for prolapse, implanted nerve stimulator for incontinence\n11. Spinal cord injury or advanced/severe neurologic conditions including Multiple Sclerosis, Parkinsons\n12. Women on anti-muscarinic therapy will be eligible after 3 week wash-out period\n13. Non-ambulatory\n14. History of serious adverse reaction to synthetic mesh\n15. Not able to complete study assessments per clinician judgment, or not available for 12 month follow-up\n16. Women who only report \"other IE\" on bladder diary, and do not report at minimum 1 stress and 1 urge IE/3 days\n17. Diagnosis of and/or history of bladder pain or chronic pelvic pain\n18. Women who had intravesical Botox injection within the past 12 months","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"21 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline UDI Total Score","description":"The Urogenital Distress Inventory (UDI) is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI scale has a range from 0 to 300 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-138.8","spread":null},{"groupId":"OG001","value":"-142.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-137","spread":null},{"groupId":"OG001","value":"-147.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-137.9","spread":null},{"groupId":"OG001","value":"-147.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline UDI Stress Score","description":"The Urogenital Distress Inventory is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI Stress subscale has a range from 0 to 100 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-70.6","spread":null},{"groupId":"OG001","value":"-72.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.5","spread":null},{"groupId":"OG001","value":"-72.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-69.3","spread":null},{"groupId":"OG001","value":"-73.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline UDI Irritative Score","description":"The Urogenital Distress Inventory is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI Irritative subscale has a range from 0 to 100 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.7","spread":null},{"groupId":"OG001","value":"-50.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-49.5","spread":null},{"groupId":"OG001","value":"-53.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50","spread":null},{"groupId":"OG001","value":"-53.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline UDI Obstructive Score","description":"The Urogenital Distress Inventory is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI Obstructive subscale has a range from 0 to 100 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.5","spread":null},{"groupId":"OG001","value":"-20.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18","spread":null},{"groupId":"OG001","value":"-21.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.5","spread":null},{"groupId":"OG001","value":"-20.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Stress Incontinence Episodes","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in number of stress incontinence episodes at 2 weeks, 2, 6, or 12 months and the number of stress incontinence episodes at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":null},{"groupId":"OG001","value":"-2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-2.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":null},{"groupId":"OG001","value":"-2.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Urge Incontinence Episodes","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in number of urge incontinence episodes at 2 weeks, 2, 6, or 12 months and the number of urge incontinence episodes at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":null},{"groupId":"OG001","value":"-1.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":null},{"groupId":"OG001","value":"-2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":null},{"groupId":"OG001","value":"-2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.9","spread":null},{"groupId":"OG001","value":"-2.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Unknown Incontinence Episodes","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in number of unknown incontinence episodes at 2 weeks, 2, 6, or 12 months and the number of unknown incontinence episodes at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Total Number of Incontinence Episodes","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in total number of incontinence episodes at 2 weeks, 2, 6, or 12 months and the total number of incontinence episodes at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":null},{"groupId":"OG001","value":"-4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":null},{"groupId":"OG001","value":"-4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":null},{"groupId":"OG001","value":"-4.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.4","spread":null},{"groupId":"OG001","value":"-4.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Wet Pads Per Day","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in number of wet pads per day at 2 weeks, 2, 6, or 12 months and the number of wet pads per day at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2","spread":null},{"groupId":"OG001","value":"-2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.4","spread":null},{"groupId":"OG001","value":"-2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":null},{"groupId":"OG001","value":"-2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":null},{"groupId":"OG001","value":"-2.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Pads Per Day","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in total number of pads per day at 2 weeks, 2, 6, or 12 months and the total number of pads per day at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":null},{"groupId":"OG001","value":"-2.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":null},{"groupId":"OG001","value":"-2.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":null},{"groupId":"OG001","value":"-2.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Daytime Voids","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in number of daytime voids at 2 weeks, 2, 6, or 12 months and the number of daytime voids at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":null},{"groupId":"OG001","value":"-0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":null},{"groupId":"OG001","value":"-1.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-2.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":null},{"groupId":"OG001","value":"-2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Nighttime Voids","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in number of nighttime voids at 2 weeks, 2, 6, or 12 months and the number of nighttime voids at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":null},{"groupId":"OG001","value":"-0.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":null},{"groupId":"OG001","value":"-0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":null},{"groupId":"OG001","value":"-0.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Number of Urgency Voids Without Incontinence","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome variable is computed as the difference in number of urgency voids without incontinence at 2 weeks, 2, 6, or 12 months and the number of urgency voids without incontinence at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.1","spread":null},{"groupId":"OG001","value":"-0.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":null},{"groupId":"OG001","value":"-4.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.5","spread":null},{"groupId":"OG001","value":"-4.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":null},{"groupId":"OG001","value":"-5.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With <8 Voids After Baseline (Normalization of Voiding Frequency)","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, for participants with \\>8 voids at baseline, the outcome is calculated as Yes=no more than 8 voids noted at the time point, No=Otherwise","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"59","spread":null}]},{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":null},{"groupId":"OG001","value":"81","spread":null}]},{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"79","spread":null}]},{"measurements":[{"groupId":"OG000","value":"56","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null},{"groupId":"OG001","value":"80","spread":null}]},{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With 50% Reduction in Voids Relative to Baseline (Improved Voiding Frequency)","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome is calculated as Yes=at least 50% reduction in the number of voids between 2 weeks, 2, 6, and 12 months and baseline, No=Otherwise","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"190","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"189","spread":null},{"groupId":"OG001","value":"177","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"155","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"153","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Number of Participants With Greater Number of Voids Relative to Baseline or >8 Voids (Worsening Voiding Frequency)","description":"Based on data collected from participant-completed diaries at baseline, 2 weeks, and 2, 6, and 12 months, the outcome is calculated as Yes=greater than baseline number of voids at the time point or with greater than 8 voids at the time point, No=Otherwise","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"124","spread":null},{"groupId":"OG001","value":"104","spread":null}]},{"measurements":[{"groupId":"OG000","value":"75","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"68","spread":null}]},{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"43","spread":null}]},{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"127","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79","spread":null},{"groupId":"OG001","value":"43","spread":null}]},{"measurements":[{"groupId":"OG000","value":"82","spread":null},{"groupId":"OG001","value":"122","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR NSAPR Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Not Partner Related subscale (NSA-PR) ranges from 0 to 100 with higher scores indicating worse function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"-8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.5","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"2.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR NSACS Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Not Sexually Active-Condition Specific subscale (NSA-CS) ranges from 0 to 100 with worse scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.8","spread":null},{"groupId":"OG001","value":"-20.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.9","spread":null},{"groupId":"OG001","value":"-16.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.5","spread":null},{"groupId":"OG001","value":"-9.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR NSAGQR Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Not Sexually Active-Global Quality Rating subscale (NSA-GQR) ranges from 0 to 100 with higher scores indicating worse function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10","spread":null},{"groupId":"OG001","value":"-14.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.8","spread":null},{"groupId":"OG001","value":"-15.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":null},{"groupId":"OG001","value":"-16.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR NSACI Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Not Sexually Active-Condition Impact subscale (NSA-CI) ranges from 0 to 100 with higher scores indicating worse function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-25.2","spread":null},{"groupId":"OG001","value":"-27.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":null},{"groupId":"OG001","value":"-23.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.8","spread":null},{"groupId":"OG001","value":"-33","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR SAAO Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Sexually Active-Arousal, Orgasm subscale (SA-AO) ranges from 0 to 100 with higher scores indicating worse function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.8","spread":null},{"groupId":"OG001","value":"10.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","spread":null},{"groupId":"OG001","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":null},{"groupId":"OG001","value":"9.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR SAPR Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Sexually Active-Partner Related subscale (SA-PR) ranges from 0 to 100 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.2","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":null},{"groupId":"OG001","value":"6.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR SACS Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Sexually Active-Condition Specific subscale (SA-CS) ranges from 0 to 100 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.1","spread":null},{"groupId":"OG001","value":"28.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"28.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.2","spread":null},{"groupId":"OG001","value":"26.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR SAGQR Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Sexually Active-Global Quality Rating subscale (SA-GQR) ranges from 0 to 100 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"18.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.1","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR SACI Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Sexually Active-Condition Impact subscale (SA-CI) ranges from 0 to 100 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.4","spread":null},{"groupId":"OG001","value":"33.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.9","spread":null},{"groupId":"OG001","value":"35.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"35.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline PISQ-IR SAD Score","description":"The Pelvic Organ Prolapse Incontinence Sexual Questionnaire, IUGA-revised (PISQ-IR) is a questionnaire measuring the impact of incontinence symptoms on sexual function and satisfaction. Using the Rockwood scoring, the PISQ-IR Sexually Active-Desire subscale (SA-D) ranges from 0 to 100 with higher scores indicating better function/satisfaction. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.8","spread":null},{"groupId":"OG001","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":null},{"groupId":"OG001","value":"5.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.7","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline EQ-5D Index Score","description":"EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life. The index score ranges from 0 to 1 with higher scores indicating a better quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline EQ-5D Visual Analog Scale Score","description":"EQ-5D is a standardized instrument developed by the EuroQol Group as a measure of health-related quality of life. The visual analog scale (VAS) score ranges from 0 to 100 with higher scores indicating a better quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"3.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline OABq-LF Symptom Severity Score","description":"The Overactive Bladder Questionnaire-Long Form is a standardized a measure of overactive bladder symptoms and health-related quality of life. The OABq-LF Symptom Severity score ranges from 0 to 100 with higher score indicating worse quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.3","spread":null},{"groupId":"OG001","value":"-46.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.4","spread":null},{"groupId":"OG001","value":"-47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.7","spread":null},{"groupId":"OG001","value":"-48.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline OABq-LF Coping Score","description":"The Overactive Bladder Questionnaire-Long Form is a standardized a measure of overactive bladder symptoms and health-related quality of life. The OABq-LF Coping score ranges from 0 to 100 with higher score indicating better quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.1","spread":null},{"groupId":"OG001","value":"48.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.3","spread":null},{"groupId":"OG001","value":"48.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"47.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline OABq-LF Concern Score","description":"The Overactive Bladder Questionnaire-Long Form is a standardized a measure of overactive bladder symptoms and health-related quality of life. The OABq-LF Concern score ranges from 0 to 100 with higher score indicating better quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.6","spread":null},{"groupId":"OG001","value":"51.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"51.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"50.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline OABq-LF Sleep Score","description":"The Overactive Bladder Questionnaire-Long Form is a standardized a measure of overactive bladder symptoms and health-related quality of life. The OABq-LF Sleep score ranges from 0 to 100 with higher score indicating better quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.7","spread":null},{"groupId":"OG001","value":"31.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.3","spread":null},{"groupId":"OG001","value":"31.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31.8","spread":null},{"groupId":"OG001","value":"32.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline OABq-LF Social Score","description":"The Overactive Bladder Questionnaire-Long Form is a standardized a measure of overactive bladder symptoms and health-related quality of life. The OABq-LF Social score ranges from 0 to 100 with higher score indicating better quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25.6","spread":null},{"groupId":"OG001","value":"26.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":null},{"groupId":"OG001","value":"26.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.1","spread":null},{"groupId":"OG001","value":"25.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline OABq-LF HRQL Total Score","description":"The Overactive Bladder Questionnaire-Long Form is a standardized a measure of overactive bladder symptoms and health-related quality of life. The OABq-LF HRQL score ranges from 0 to 100 with higher score indicating better quality of life. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"41.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"41.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.6","spread":null},{"groupId":"OG001","value":"41.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"OAB-SATq Satisfaction Score","description":"The Overactive Bladder Satisfaction with Treatment Questionnaire is a standardized a measure of satisfaction with treatment for overactive bladder symptoms. The OAB-SATq Satisfaction score ranges from 0 to 100 with higher scores indicating higher satisfaction.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.8","spread":null},{"groupId":"OG001","value":"18.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":null},{"groupId":"OG001","value":"17.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"OAB-SATq Side Effect Score","description":"The Overactive Bladder Satisfaction with Treatment Questionnaire is a standardized a measure of satisfaction with treatment for overactive bladder symptoms. The OAB-SATq Side Effect score ranges from 0 to 100 with higher scores indicating fewer side effects.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"84.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"79.7","spread":null},{"groupId":"OG001","value":"87.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"86.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"OAB-SATq Endorsement Score","description":"The Overactive Bladder Satisfaction with Treatment Questionnaire is a standardized a measure of satisfaction with treatment for overactive bladder symptoms. The OAB-SATq Endorsement score ranges from 0 to 100 with higher scores indicating greater endorsement.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":null},{"groupId":"OG001","value":"8.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.2","spread":null},{"groupId":"OG001","value":"6.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"8.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"OAB-SATq Convenience Score","description":"The Overactive Bladder Satisfaction with Treatment Questionnaire is a standardized a measure of satisfaction with treatment for overactive bladder symptoms. The OAB-SATq Convenience score ranges from 0 to 100 with higher scores indicating greater convenience.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"25.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.1","spread":null},{"groupId":"OG001","value":"26.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"21.3","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"OAB-SATq Preference Score","description":"The Overactive Bladder Satisfaction with Treatment Questionnaire is a standardized a measure of satisfaction with treatment for overactive bladder symptoms. The preference score is a binary \\[yes/no\\] indicator as to whether a subject indicated slight or definite preference for the treatment among women that have had previous treatment for overactive bladder. The outcome is the percentage of participants that prefer the current treatment to previous treatments.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"111","spread":null},{"groupId":"OG001","value":"109","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null},{"groupId":"OG001","value":"112","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"107","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline IIq-LF Physical Activity Score","description":"The Incontinence Impact Questionnaire-Long Form is a standardized a measure of health-related quality of life. The IIq-LF Physical Activity score ranges from 0 to 100 with higher scores indicating worse impact. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.2","spread":null},{"groupId":"OG001","value":"-40.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-39.1","spread":null},{"groupId":"OG001","value":"-42.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.3","spread":null},{"groupId":"OG001","value":"-42.5","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline IIq-LF Travel Score","description":"The Incontinence Impact Questionnaire-Long Form is a standardized a measure of health-related quality of life. The IIq-LF Travel score ranges from 0 to 100 with higher scores indicating worse impact. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.9","spread":null},{"groupId":"OG001","value":"-38.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.4","spread":null},{"groupId":"OG001","value":"-40.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.4","spread":null},{"groupId":"OG001","value":"-40.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline IIq-LF Social Relationship Score","description":"The Incontinence Impact Questionnaire-Long Form is a standardized a measure of health-related quality of life. The IIq-LF Social Relationship score ranges from 0 to 100 with higher scores indicating worse impact. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.9","spread":null},{"groupId":"OG001","value":"-32.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.6","spread":null},{"groupId":"OG001","value":"-33.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-30","spread":null},{"groupId":"OG001","value":"-34.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline IIq-LF Emotional Health Score","description":"The Incontinence Impact Questionnaire-Long Form is a standardized a measure of health-related quality of life. The IIq-LF Emotional Health score ranges from 0 to 100 with higher scores indicating worse impact. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.4","spread":null},{"groupId":"OG001","value":"-40.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.6","spread":null},{"groupId":"OG001","value":"-41.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-38.3","spread":null},{"groupId":"OG001","value":"-42.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline IIq-LF Total Score","description":"The Incontinence Impact Questionnaire-Long Form is a standardized a measure of health-related quality of life. The IIq-LF Total score ranges from 0 to 400 with higher scores indicating worse impact. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-140.4","spread":null},{"groupId":"OG001","value":"-153.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-139.8","spread":null},{"groupId":"OG001","value":"-158.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-146","spread":null},{"groupId":"OG001","value":"-160.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline ADI Hygiene Score","description":"The Adaptation Index is a standardized measure of health-related quality of life. The ADI Hygiene score ranges from 0 to 100 with higher score indicating worse severity in adaptive behaviors. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.1","spread":null},{"groupId":"OG001","value":"-36.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.6","spread":null},{"groupId":"OG001","value":"-37.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-35.5","spread":null},{"groupId":"OG001","value":"-38.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline ADI Avoidance Score","description":"The Adaptation Index is a standardized measure of health-related quality of life. The ADI Avoidance score ranges from 0 to 100 with higher score indicating worse severity in adaptive behaviors. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-31.3","spread":null},{"groupId":"OG001","value":"-33.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.5","spread":null},{"groupId":"OG001","value":"-34.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-33","spread":null},{"groupId":"OG001","value":"-35.7","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Baseline Brink Score","description":"The Brink scale considers three pelvic floor muscle contraction variables: vaginal pressure or muscle force, elevation or vertical displacement of the examiner fingers, and duration of contraction. The score ranges from 3 to 12 with higher scores indicating greater PFM function. The change from baseline outcome is calculated as the difference in score at 3 or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change From Average Peak Muscle Contraction Pressure (cm H2O)","description":"The average peak muscle contraction is measured during a physical exam. The outcome is calculated as the difference in measured value at 3 or 12 months and the score at baseline.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"4.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4.4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"PGI-I","description":"The Patient Global Impression of Improvement (PGI-I) is a patient-reported measure of perceived improvement with treatment, as assessed on a scale of 1 (very much better) to 7 (very much worse). Included here are participants who had improvement as indicated by a rating of 1 (very much better), 2 (much better).","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":null},{"groupId":"OG001","value":"178","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"168","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"147","spread":null},{"groupId":"OG001","value":"159","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"22","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"PGI-S","description":"The Patient Global Impression of Severity (PGI-S) is a patient-reported measure of perceived severity of condition, as assessed on a scale of 1 (Normal) to 4 (Severe). Included here are participants who reported Normal or Mild severity as indicated by a rating of 1 or 2.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"48","spread":null}]},{"measurements":[{"groupId":"OG000","value":"188","spread":null},{"groupId":"OG001","value":"187","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"174","spread":null}]},{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"166","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"164","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":238},"commonTop":["Urinary tract infection","Urinary retention","Back pain","Arthralgia","Dyspareunia"]}}}